Progenics Pharmaceuticals Inc
PGNX
PGNX was delisted on the 19th of June, 2020.
152 hedge funds and large institutions have $478M invested in Progenics Pharmaceuticals Inc in 2018 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 63 increasing their positions, 37 reducing their positions, and 21 closing their positions.
70% more repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 37
40% more capital invested
Capital invested by funds: $341M → $478M (+$137M)
14% more call options, than puts
Call options by funds: $12M | Put options by funds: $10.6M
0% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 21
1% less funds holding
Funds holding: 153 → 152 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$16M |
| 2 |
PFC
Phocas Financial Corp
Alameda,
California
|
+$2.26M |
| 3 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
+$2.06M |
| 4 |
State Street
Boston,
Massachusetts
|
+$2M |
| 5 |
AAP
Ardsley Advisory Partners
Stamford,
Connecticut
|
+$1.99M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$5.62M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.55M |
| 3 |
CCM
Cadence Capital Management
Boston,
Massachusetts
|
-$1.55M |
| 4 |
PA
Pinnacle Associates
New York
|
-$741K |
| 5 |
LCM
Landscape Capital Management
Englewood,
New Jersey
|
-$514K |
PGNX Hedge Fund Activity: Q1 2018 in Review
152 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Progenics Pharmaceuticals Inc (PGNX) for Q1 2018, worth a combined $478M — up 40% from $341M a quarter earlier.
Fund positioning in PGNX was balanced in Q1 2018: 21 funds opened new positions, 21 closed out, 63 added to existing stakes and 37 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $16M. The largest seller was Baker Bros. Advisors, cutting an estimated $5.62M.
- 152 institutional investors held Progenics Pharmaceuticals Inc (PGNX) as of Q1 2018, down from 153 in Q4 2017.
- Funds reported $478M of Progenics Pharmaceuticals Inc stock for Q1 2018, up 40% quarter-over-quarter.
- 21 funds opened new Progenics Pharmaceuticals Inc positions in Q1 2018 and 21 closed out, a net change of 0 holders.
- The largest Progenics Pharmaceuticals Inc buyer in Q1 2018 was Armistice Capital, an estimated $16M added.
- The largest Progenics Pharmaceuticals Inc seller in Q1 2018 was Baker Bros. Advisors, an estimated $5.62M sold.
Based on aggregated 13F filings for Q1 2018.